Lindsay Fischer

The FDA has granted blinatumomab full approval for patients with minimal residual disease–positive B-cell acute lymphoblastic leukemia.

AnnMarie Walton, PhD, MPH, RN, OCN, CHES, FAAN, discusses the limitations of plastic-backed pads in inpatient oncology units.

Second-line treatment with CDK4/6 inhibition was associated with fewer toxicities and drug costs than frontline CDK4/6 inhibitor treatment—although progression-free survival and overall survival outcomes were similar.

Lauren Mahon, MSN, FNP-BC, outlines nursing considerations with approved PARP inhibitors.

Glofitamab has received accelerated approval for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma.

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

Omitting radiotherapy did not compromise overall survival rates for patients with primary mediastinal B-cell lymphoma.

Axicabtagene ciloleucel delivered superior overall survival compared with standard of care in patients with early relapsed or refractory large B-cell lymphoma.

An analysis of patient-reported outcomes in the phase 3 RUBY trial supports dostarlimab use in patients with primary advanced or recurrent endometrial cancer.

Tremelimumab plus durvalumab (STRIDE) showed a manageable immune-related adverse event profile in the phase 3 HIMALAYA trial.

Research published in the Clinical Journal of Oncology Nursing supports current guideline recommendations for washing clothes contaminated with cyclophosphamide.

Seth Eisenberg, ASN, RN, OCN, BMTCN, emphasizes the importance of reducing nurse exposure to hazardous drugs—and ongoing research efforts to improve nursing safety.

The FDA has approved olaparib for patients with BRCA-positive metastatic castration-resistant prostate cancer (mCRPC), as determined by an FDA-approved companion diagnostic test.

Patients with heavily pretreated advanced melanoma achieved responses with nivolumab and relatlimab.

Patient navigation services increased the rates of breast, cervical, and colorectal cancer screenings 6-fold amongst women living in rural communities.

Fit patients with chronic lymphocytic leukemia achieved high undetectable minimal residual disease rates with frontline venetoclax combinations.

The FDA has approved avapritinib for the treatment of patients with indolent systemic mastocytosis.

The FDA has granted epcoritamab accelerated approval for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. The prescribing label comes with boxed warnings for cytokine release syndrome and neurologic problems.

Cabozantinib, in combination with nivolumab and ipilimumab, improved progression-free survival in patients with advanced renal cell carcinoma, but the rate of grade 3/4 adverse events was 79%.

Amber Pierce RN, BSN, OCN, highlights the importance of a 2-step verification process with fixed-dose regimen therapies.

Research published in JAMA Oncology suggest that acute radiation dermatitis may be the result of a common skin bacterium and prevented with a low-cost topical treatment.

Patient-reported outcomes among patients who received elacestrant were consistent with other endocrine therapies.

Krista M. Rubin, RN, MS, FNP-BC, highlights how nurses can help patients with uveal melanoma anticipate and manage adverse events during the step-up dosing period with tebentafusp.

The Splashblocker was found to be an effective way to reduce contaminated particles. Plastic backed pads had mixed reviews.

Kathleen Gander DNP, APRN, CNS; and Sarah Middlekauff, MSN, RN, OCN, relay their experiences in implementing a hepatic artery infusion pump educational intervention for oncology nurses.

Managing ocular-related adverse effects with mirvetuximab soravtansine is key to helping patients with ovarian cancer stay on treatment.

Victoria R. Crowder, BSN, RN, and co-investigators, highlight existing gaps in the understanding of malnutrition risks facing patients with acute myeloid leukemia and myelodysplastic syndromes.

Denise Nicholson, BSN, RN, explains the importance of advance care planning, and how oncology nurses can effectively facilitate these conversations.

A genome-wide methylome enrichment platform may help identify multiple early-stage cancers.

Polatuzumab vedotin has been approved in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone for previously untreated diffuse large B-cell lymphoma.